Anandamide Induces Platelet Nitric Oxide Synthase through AMP-Activated Protein Kinase

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Endothelial nitric oxide synthase (eNOS) plays a critical role in vascular homeostasis.
• Adenosine 5' monophosphate (AMP)-activated protein kinase (AMPK) is a key cellular energy sensor.
• Anandamide (AEA) is an endogenous cannabinoid with potential signaling roles.

Purpose of the Study:

• To investigate if anandamide (AEA) activates AMPK.
• To determine if AEA-mediated AMPK activation is involved in endothelial nitric oxide synthase (eNOS) activation.
• To elucidate the signaling pathways linking AEA, AMPK, and eNOS.

Main Methods:

• Utilized specific inhibitors: STO-609 (CaMKKβ), LY294002 (PI3K), MK2206 (AKT), SR141716 (CB1), and SR144528 (CB2).
• Assessed AMPK and VASP phosphorylation.
• Measured nitric oxide (NO) and guanosine 3'-5' cyclic monophosphate (cGMP) levels.
• Investigated Ca2+/Calmodulin (CaM) dependence.

Main Results:

• AEA activates AMPK via a Ca2+/CaM-dependent pathway involving CaMKKβ, downstream of PI3K/AKT.
• AEA-induced eNOS activation, leading to increased NO and cGMP, is mediated by CaMKKβ/AMPKα.
• AEA stimulates VASP phosphorylation, dependent on the CaMKKβ/AMPKα pathway and CB1 receptor activation.

Conclusions:

• Anandamide (AEA) activates the CaMKKβ/AMPKα pathway in human platelets, downstream of PI3K/AKT.
• This activation increases nitric oxide (NO) levels, offering potential benefits in ischemic conditions and extending platelet survival.
• The type 1 cannabinoid receptor (CB1) is primarily involved in AEA's effects.